CERTCertara, Inc.
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~5% a year FCF growth. Roughly in line with its three-year revenue growth of 5% a year.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CERT's price assumes
Today's price asks for 5.4% free cash flow growth a year; over the last three years Certara, Inc. delivered −2.4%, so the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 5.1%
Free cash flow yield · Health Information Services median 4.5%
- Growth the price implies
- +5.4%
Growth the price implies · The price pays for +5.4% free cash flow growth a year for a decade; the business has delivered −2.4% a year over the last three.
- Price / book
- 1.05
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 1.05
- EV / EBIToperating margin −0.16%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 2.74
- Free cash flow, trailing twelve months
- $80M
- Market capitalisation152.5 million shares, counted Aug 1, 2026
- $1.58B
- 3-year revenue growth
- +5.1%
- 3-year free cash flow growth
- −2.4%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Health Information Services
Ranks #9 of 18 by RyuScore